FDA found DuPont released Avicel excipient that failed conductivity limits, citing weak investigations and data integrity lapses.
What happened
FDA inspected the Newark, Delaware plant that makes Avicel, a non-active drug ingredient (an excipient), from November 17 to December 15, 2021. Investigators found about 50 customer complaints from April 2020 to June 2021 that Avicel failed the USP conductivity standard; the conductivity meter probe was encrusted with residue and gave falsely low readings, failing lots had already been shipped, and customers were not told for months. The inspection also found retests that turned failing results into passing ones, backdated laboratory records, use of unreleased microbiological growth media, unverified and unvalidated test methods, and conductivity meters removed without documented change control.
What FDA found
About 50 customer complaints that Avicel failed the conductivity standard were not adequately investigated, and affected batches were shipped and not reported to customers for months.
FD&C Act 501(a)(2)(B)Out-of-specification (outside the allowed limit) test results were not fully or promptly investigated, and the probe caked with grime that caused falsely low readings was not traced to other affected lots in good time.
FD&C Act 501(a)(2)(B)The conductivity test methods were not properly verified or validated, and a quick in-house method that read much lower than the USP method was approved for production release testing.
FD&C Act 501(b)Conductivity meters were removed around 2011 without a documented change control, even though conductivity had been identified as a critical quality parameter.
FD&C Act 501(a)(2)(B)Failing pH, conductivity, loss on drying and particle size results were changed to passing by retesting without adequate investigation or justification.
FD&C Act 501(a)(2)(B)Laboratory staff backdated the approval on a microbiological media worksheet and used unreleased growth media plates for drug testing, and test records lacked sample weights and instrument references.
FD&C Act 501(a)(2)(B)
What FDA wants
FDA tells the company to reply in writing within 15 working days with what it has done and will do, including independent assessments and remediation plans for complaint handling, OOS investigations, test method verification and validation, change management and data integrity, plus a retrospective review of invalidated OOS results and released lots. FDA strongly recommends hiring a qualified third-party consultant and says to contact its Drug Shortages Staff immediately if corrective action could disrupt supply.
Who should pay attention
- drug manufacturers that use Avicel (MCC) as an excipient
- quality teams at excipient makers and contract testing labs
- companies that rely on supplier certificates of analysis for release
This is a summary. Read the original letter on fda.gov.